[{"id":"0d8d95d1-e811-40d1-bfc3-cea16cccfecf","acronym":"CARRIE","url":"https://clinicaltrials.gov/study/NCT02399137","created_at":"2021-01-18T11:26:45.591Z","updated_at":"2024-07-02T16:37:06.821Z","phase":"Phase 2","brief_title":"A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02399137 - CARRIE","lead_sponsor":"Merrimack Pharmaceuticals","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • istiratumab (MM-141)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2018","study_completion_date":" 08/01/2018","last_update_posted":"2018-09-18"}]